GlassScriptPhysician profile
Larissa Moon
NPI 1437810280
$972.01
in general payments reported to CMS, 2019-2025
14 companies · $256 in 2025
The $256 reported for 2025 was more than what 81% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $50.37 · 2024: $665 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $195.69 | 2024 | Qelbree |
| Ucb, INC. | $170.77 | 2023-2024 | Briviact |
| Azurity Pharmaceuticals, INC. | $156.49 | 2024-2025 | Triptodur, Zonisade |
| Acadia Pharmaceuticals INC | $119.60 | 2023-2024 | Daybue |
| Jazz Pharmaceuticals INC. | $70.40 | 2024 | |
| Livanova USA, INC. | $55.31 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Ironshore Pharmaceuticals INC. | $39.33 | 2024 | |
| Sequel Med Tech, LLC | $35.43 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $33.73 | 2025 | |
| Endo USA, INC. | $24.15 | 2025 | Supprelin |
| Vertical Pharmaceuticals, LLC | $21.70 | 2024 | Relexxii |
| Tris Pharma INC | $18.04 | 2024 | Dyanavel Xr |
| Tolmar, INC. | $16.90 | 2025 | Fensolvi |
| Eton Pharmaceuticals, INC. | $14.47 | 2025 | Khindivi, Alkindi, Increlex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.